Literature DB >> 15363630

Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.

Patrick S Moore1, Stefano Barbi, Massimo Donadelli, Chiara Costanzo, Claudio Bassi, Marta Palmieri, Aldo Scarpa.   

Abstract

The histone deacetylase inhibitor trichostatin A (TSA) has been previously shown to block cellular growth in G2 and induce apoptosis in human pancreatic cancer cell lines. In order to better understand this phenomenon, we have analyzed the gene expression profiles in PaCa44 cells after treatment with TSA using microarrays containing 22,283 probesets. TSA was found to cause both the induction and repression of a large number of genes, although the number whose expression was up-regulated was greater than the number of genes that were down-regulated. When a threshold value of 3 was used as a cutoff level, a total of 306 (3.4%) of the detectable genes had altered expression. When categorized according to cellular function, the differentially expressed genes were found to be involved in a wide variety of cellular processes, including cell proliferation, signaling, regulation of transcription, and apoptosis. Moreover, Sp1/Sp3 transcription factor binding sites were significantly more abundant among TSA-induced genes. One prominent feature was the increased ratio between the levels of expression of pro-apoptotic (BIM) and anti-apoptotic (Bcl-XL and Bcl-W) genes. This result was confirmed in eight additional pancreatic cancer cell lines after treatment with TSA, suggesting that this event may be a strong determinant for the induction of apoptosis by TSA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363630     DOI: 10.1016/j.bbamcr.2004.07.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  33 in total

1.  The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells.

Authors:  Ke Long Jin; Jeong-Yeol Park; Eun Joo Noh; Kwang Lae Hoe; Joo Hak Lee; Jong-Hyeok Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

Review 2.  Current evidence for histone deacetylase inhibitors in pancreatic cancer.

Authors:  Ioannis Koutsounas; Constantinos Giaginis; Efstratios Patsouris; Stamatios Theocharis
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 3.  Unfolding antifungals: as a new foe to pancreatic ductal adenocarcinoma-a mini-review.

Authors:  Shruti Gupta; Atul Kumar; Kiran Kumar Tejavath
Journal:  Mol Biol Rep       Date:  2021-04-01       Impact factor: 2.316

Review 4.  Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.

Authors:  Sau Wai Hung; Hardik R Mody; Rajgopal Govindarajan
Journal:  Cancer Lett       Date:  2012-03-13       Impact factor: 8.679

5.  A feed-forward repression mechanism anchors the Sin3/histone deacetylase and N-CoR/SMRT corepressors on chromatin.

Authors:  Michiel Vermeulen; Wendy Walter; Xavier Le Guezennec; Jaehoon Kim; Rajeswari S Edayathumangalam; Edwin Lasonder; Karolin Luger; Robert G Roeder; Colin Logie; Shelley L Berger; Hendrik G Stunnenberg
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

6.  Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

Authors:  Paolo Piacentini; Massimo Donadelli; Chiara Costanzo; Patrick S Moore; Marta Palmieri; Aldo Scarpa
Journal:  Virchows Arch       Date:  2006-03-28       Impact factor: 4.064

7.  Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer.

Authors:  Raghu Gogada; Neelu Yadav; Junwei Liu; Shaohua Tang; Dianmu Zhang; Andrea Schneider; Athul Seshadri; Leimin Sun; C Marcelo Aldaz; Dean G Tang; Dhyan Chandra
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

8.  A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Authors:  Jhanelle E Gray; Eric Haura; Alberto Chiappori; Tawee Tanvetyanon; Charles C Williams; Mary Pinder-Schenck; Julie A Kish; Jenny Kreahling; Richard Lush; Anthony Neuger; Leticia Tetteh; Angela Akar; Xiuhua Zhao; Michael J Schell; Gerold Bepler; Soner Altiok
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

Review 9.  Histone deacetylase regulation of immune gene expression in tumor cells.

Authors:  A Nazmul H Khan; Thomas B Tomasi
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines.

Authors:  Mario Dandrea; Massimo Donadelli; Chiara Costanzo; Aldo Scarpa; Marta Palmieri
Journal:  Nucleic Acids Res       Date:  2009-09-10       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.